Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 102kWORD 28k
23 June 2015
E-004613/2015(ASW)
Answer given by Ms Bieńkowska on behalf of the Commission
Question reference: E-004613/2015

The Commission would like to refer the Honourable Member to its replies to questions P-000227/2015, P-000293/2015 and E-000205/2015(1).

Substantive patent law is today predominantly covered in the national laws which lay down the scope of the rights conferred by a patent and contain limitations of the effects of a patent. National patent laws deal also with compulsory licenses. It is for each individual Member State to interpret its national patent law provisions and to assess whether the applicable conditions for exceptions and limitations apply.

The Global Burden of Disease project has amongst others examined morbidity and mortality associated with hepatitis. Currently the Commission is funding an ongoing project on ‘HCV Treatment as Prevention in Europe’. In addition, the European Network for Health Technology Assessment a Commission co-funded joint action has assessed Sofosbuvir and is currently assessing other compounds for the treatment of hepatitis C.

Neither the Commission nor the European Medicines Agency (EMA) have a mandate to acquire individual patents for general public objectives..

(1)http://www.europarl.europa.eu/plenary/en/parliamentary-questions.html

Legal notice - Privacy policy